1887

Abstract

Antifungal drugs have already been established as an effective treatment option for infections, but there is no universal consensus on the ideal target for clinical efficacy and safety of antifungal drugs for the treatment of infections. Few studies have directly compared the efficacies of antifungal drugs for the treatment of infections. We hypothesize that different antifungal drugs offer differing clinical efficacy and safety for the treatment of infections. We performed a comprehensive network meta-analysis on different strategies for infection treatment and compared the clinical efficacy and safety of antifungal drugs as interventions for infections. The Cochrane Database of Systematic Reviews, Medline, Embase, PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), Technology of Chongqing VIP database, Wan Fang Data, and SinoMed databases were searched to identify appropriate randomized trials. Among the extracted cases, the survival and death rates with treatment of infection were compared among groups treated with different antifungal drugs. According to the evidence-network analysis, echinocandins were a better choice than other drugs for treating infections, and more importantly, caspofungin showed a more preferable effect for decreasing the risk of 30 day mortality. In conclusion, this study systematically evaluated the effectiveness and safety of antifungal drugs for the purpose of helping clinicians choose the most appropriate antifungal drugs. Future studies with larger samples are needed to evaluate the effects of patient factors on the clinical efficacy and safety of antifungal drugs for infections.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001434
2021-10-11
2021-10-25
Loading full text...

Full text loading...

/deliver/fulltext/jmm/70/10/jmm001434.html?itemId=/content/journal/jmm/10.1099/jmm.0.001434&mimeType=html&fmt=ahah

References

  1. Almirante B, Rodríguez D, Cuenca-Estrella M, Almela M, Sanchez F et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006; 44:1681–1685 [View Article] [PubMed]
    [Google Scholar]
  2. Chang MR, Correia FP, Costa LC, Xavier PC, Palhares DB et al. Candida bloodstream infection: data from a teaching hospital in Mato Grosso do Sul. Rev Inst Med Trop Sao Paulo 2008; 50:265–268S0036-46652008000500003 [View Article] [PubMed]
    [Google Scholar]
  3. Saxen H, Virtanen M, Carlson P, Hoppu K, Pohjavuori M et al. Neonatal Candida parapsilosis outbreak with a high case fatality rate. Pediatr Infect Dis J 1995; 14:776–781 [View Article] [PubMed]
    [Google Scholar]
  4. Quindós G. Epidemiology of candidaemia and invasive candidiasis. A changing face. Rev Iberoam Micol 2014; 31:42–48S1130-1406(13)00101-0 [View Article] [PubMed]
    [Google Scholar]
  5. Wang H, Xiao M, Chen SC, Kong F, Sun ZY et al. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study. J Clin Microbiol 2012; 50:3952–3959 [View Article] [PubMed]
    [Google Scholar]
  6. Levy I, Rubin LG, Vasishtha S, Tucci V, Sood SK. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis 1998; 26:1086–1088 [View Article] [PubMed]
    [Google Scholar]
  7. Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008; 21:606–625 [View Article] [PubMed]
    [Google Scholar]
  8. Bonassoli LA, Bertoli M, Svidzinski TI. High frequency of Candida parapsilosis on the hands of healthy hosts. J Hosp Infect 2005; 59:159–162 [View Article] [PubMed]
    [Google Scholar]
  9. Clark TA, Slavinski SA, Morgan J, Lott T, Arthington-Skaggs BA et al. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol 2004; 42:4468–4472 [View Article] [PubMed]
    [Google Scholar]
  10. Tosun I, Akyuz Z, Guler NC, Gulmez D, Bayramoglu G et al. Distribution, virulence attributes and antifungal susceptibility patterns of Candida parapsilosis complex strains isolated from clinical samples. Med Mycol 2013; 51:483–492 [View Article] [PubMed]
    [Google Scholar]
  11. Jebabli N, Salouage I, Gaies E, Trabelsi S, Charfi R et al. Interaction between tacrolimus and azole antifugal drugs. Drug Saf 2011
    [Google Scholar]
  12. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125:S3–13 [View Article] [PubMed]
    [Google Scholar]
  13. Chen JF, Miao CY, Xu P. Advance in research for clinical pharmacokinetics on antifugal drug of voriconazole. Chinese Journal of Clinical Pharmacology and Therapeutics 2015; 9:
    [Google Scholar]
  14. Hua S, Huang J, Wu Z, Feng Z. A comparison study between Candida parapsilosis sepsis and Candida albicans sepsis in preterm infants. Turk J Pediatr 2012; 54:502–508 [PubMed]
    [Google Scholar]
  15. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331:1325–1330 [View Article] [PubMed]
    [Google Scholar]
  16. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020–2029 [View Article] [PubMed]
    [Google Scholar]
  17. Colombo AL, Perfect J, DiNubile M, Bartizal K, Motyl M et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22:470–474 [View Article] [PubMed]
    [Google Scholar]
  18. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883–893 [View Article] [PubMed]
    [Google Scholar]
  19. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472–2482 [View Article] [PubMed]
    [Google Scholar]
  20. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369:1519–1527S0140-6736(07)60605-9 [View Article] [PubMed]
    [Google Scholar]
  21. Kullberg BJ, Viscoli C, Pappas PG, Vazquez J, Ostrosky-Zeichner L et al. Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections. Clin Infect Dis 2019; 68:1981–1989 [View Article] [PubMed]
    [Google Scholar]
  22. Gauna TT, Oshiro E, Luzio YC, Paniago AM, Pontes ER et al. Bloodstream infection in patients with end-stage renal disease in a teaching hospital in central-western Brazil. Rev Soc Bras Med Trop 2013; 46:426–432 [View Article] [PubMed]
    [Google Scholar]
  23. Girmenia C, Martino P, De Bernardis F, Gentile G, Boccanera M et al. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis 1996; 23:506–514 [View Article] [PubMed]
    [Google Scholar]
  24. Huang YC, Lin TY, Leu HS, Peng HL, Wu JH et al. Outbreak of Candida parapsilosis fungemia in neonatal intensive care units: clinical implications and genotyping analysis. Infection 1999; 27:97–102 [View Article] [PubMed]
    [Google Scholar]
  25. Borghi E, Sciota R, Iatta R, Biassoni C, Montagna MT et al. Characterization of Candida parapsilosis complex strains isolated from invasive fungal infections. Eur J Clin Microbiol Infect Dis 2011; 30:1437–1441 [View Article] [PubMed]
    [Google Scholar]
  26. Cisneros Herreros JM, Cordero Matía E. Therapeutic armamentarium against systemic fungal infections. Clin Microbiol Infect 2006; 12:53–64 [View Article]
    [Google Scholar]
  27. Kohno S, Izumikawa K, Yoshida M, Takesue Y, Oka S et al. A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Eur J Clin Microbiol Infect Dis 2013; 32:387–397 [View Article] [PubMed]
    [Google Scholar]
  28. Kawai A, Yamagishi Y, Mikamo H. In vitro efficacy of liposomal amphotericin B, micafungin and fluconazole against non-albicans Candida species biofilms. J Infect Chemother 2015; 21:647–653S1341-321X(15)00132-4 [View Article] [PubMed]
    [Google Scholar]
  29. Wang F, Wang LU. Analysis of the utilization of antifungal agents in our hospital during 2007-2009. Chinese General Practice 2012; 15:324–327
    [Google Scholar]
  30. Feng JW. Clinical analysis of candidal vaginitis patients and drug resistance. China Tropical Medicine 2007; 39:574–580
    [Google Scholar]
  31. Yamaguchi H. Basal studies and preclinical evaluations of newly developed antifungal agents. Nippon Ishinkin Gakkai Zasshi 2009; 26:116–125
    [Google Scholar]
  32. Zeng R, Li M, Chen Q, Wang L, GX LV et al. Dynamic study on the susceptibilities of caspofungin and micafungin to Candida species in vitro. Chinese Journal of Mycology 2011; 5:
    [Google Scholar]
  33. Nawaz A, Pärnänen P, Kari K, Meurman JH. Proteolytic activity and cytokine up-regulation by non-albicans Candida albicans. Arch Microbiol 2015; 197:533–537 [View Article] [PubMed]
    [Google Scholar]
  34. Freemantle N, Tharmanathan P, Herbrecht R. Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. J Antimicrob Chemother 2011; 66 Suppl 1:i25–35 [View Article] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001434
Loading
/content/journal/jmm/10.1099/jmm.0.001434
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error